The prevalence of Parkinson's disease: A systematic review and meta-analysis, Mov. Disord, vol.29, pp.1583-1590, 2014. ,
Parkinson's disease: Clinical features and diagnosis, J. Neurol. Neurosurg. Psychiatry, vol.79, pp.368-376, 2008. ,
, Nat. Rev. Dis. Primers, vol.3, p.17013, 2017.
, Lewy bodies, vol.388, pp.839-840, 1997.
Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes, Nat. Neurosci, vol.22, pp.1099-1109, 2019. ,
Mutation in the ?-Synuclein Gene Identified in Families with Parkinson's Disease, Science, vol.276, pp.2045-2047, 1997. ,
Conformational properties of alpha-synuclein in its free and lipid-associated states, J. Mol. Biol, vol.307, pp.1061-1073, 2001. ,
alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation, Nature, vol.477, pp.107-110, 2011. ,
Properties of native brain alphasynuclein, Nature, vol.498, pp.4-6, 2013. ,
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly, J. Biol. Chem, vol.276, pp.2380-2386, 2001. ,
In vivo demonstration that alpha-synuclein oligomers are toxic, Proc Natl Acad Sci, vol.108, pp.4194-4199, 2011. ,
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models, EMBO J, vol.28, pp.3256-3268, 2009. ,
, Synuclein strains target distinct brain regions and cell types, vol.2020, pp.21-31
Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy, Nature, vol.578, pp.273-277, 2020. ,
Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies, Nature, vol.557, pp.558-563, 2018. ,
Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus, Nat. Commun, 2011. ,
Alpha-Synuclein, a Novel Viral Restriction Factor Hiding in Plain Sight, DNA Cell Biol, vol.35, pp.643-645, 2016. ,
Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans, Sci. Rep, vol.6, p.34477, 2016. ,
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein, J. Biol. Chem, vol.277, pp.1641-1644, 2002. ,
Formation and Implications of Alpha-Synuclein Radical in Maneb-and Paraquat-Induced Models of Parkinson's Disease, Mol. Neurobiol, vol.53, pp.2983-2994, 2016. ,
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1, Nature, vol.468, pp.696-700, 2010. ,
Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease, Exp. Neurol, vol.298, pp.202-209, 2017. ,
Neuroinflammation in Parkinson's disease: A target for neuroprotection?, Lancet. Neurol, vol.8, pp.382-397, 2009. ,
Targeting ?-synuclein for treatment of Parkinson's disease: Mechanistic and therapeutic considerations, Lancet. Neurol, vol.14, pp.855-866, 2015. ,
Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal, J. Neurosci, vol.8, pp.2804-2815, 1988. ,
Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro, Science, vol.329, pp.1663-1667, 2010. ,
Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking, Proc. Natl Acad Sci, vol.110, pp.4087-4092, 2013. ,
Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alphasynuclein and gamma-synuclein, Eur. J. Neurosci, vol.27, pp.947-957, 2008. ,
Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family, J. Neurosci, vol.31, pp.7264-7274, 2011. ,
Dopamine induces soluble alpha-synuclein oligomers and nigrostriatal degeneration, Nat. Neurosci, vol.20, pp.1560-1568, 2017. ,
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease, vol.357, pp.1255-1261, 2017. ,
Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alphasynuclein-induced toxicity, Hum. Mol. Genet, vol.14, pp.3801-3811, 2005. ,
Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death, Neuron, vol.72, pp.57-71, 2011. ,
Structural and functional characterization of two alpha-synuclein strains, Nat. Commun, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01183047
alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells, J. Clin. Invest, vol.121, pp.715-725, 2011. ,
Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease, Mov. Disord, vol.28, pp.811-813, 2013. ,
AlaSOPro mutation in the gene encoding ?-synuclein in Parkinson's disease, Nat. Genet, vol.18, pp.106-108, 1998. ,
G51D ?-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome, Ann. Neurol, vol.73, pp.459-471, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01133851
A novel ?-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology, Neurobiol. Aging, vol.35, 2014. ,
A novel ?-synuclein missense mutation in Parkinson disease, Neurology, vol.80, pp.1062-1064, 2013. ,
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia, Ann. Neurol, vol.55, pp.164-173, 2004. ,
Homozygous alpha-synuclein p.A53V in familial Parkinson's disease, Neurobiol. Aging, vol.57, p.212, 2017. ,
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease, Lancet, vol.364, pp.17103-17104, 2004. ,
, Synuclein Locus Triplication Causes Parkinson's Disease, vol.302, pp.841-841, 2003.
Gene dosage and pathogenesis of Parkinson's disease, Trends Mol. Med, vol.11, pp.91-96, 2005. ,
Comparison of kindreds with parkinsonism and ?-synuclein genomic multiplications, Ann. Neurol, vol.55, pp.174-179, 2004. ,
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, vol.391, pp.806-811, 1998. ,
Gene Silencing by Small Regulatory RNAs in Mammalian Cells, Cell Cycle, vol.6, pp.444-449, 2007. ,
Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi, Exp. Neurol, vol.198, pp.382-390, 2006. ,
Down-regulation of alphasynuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model, Biochem. Biophys. Res. Commun, vol.341, pp.1088-1095, 2006. ,
In vivo silencing of alpha-synuclein using naked siRNA, Mol. Neurodegener, 2008. ,
Repression of ?-synuclein expression and toxicity by microRNA-7, Proc. Natl. Acad. Sci, vol.106, p.13052, 2009. ,
Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153, J. Biol. Chem, vol.285, pp.12726-12734, 2010. ,
In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration, Mol. Therapy, vol.18, pp.1450-1457, 2010. ,
An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons, Brain Res, vol.1395, pp.94-107, 2011. ,
A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons, Brain Res, vol.1386, pp.15-24, 2011. ,
Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects, Brain Res, vol.1550, pp.47-60, 2014. ,
Is Alpha-Synuclein Lossof-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates, Front. Neurosci, vol.10, p.12, 2016. ,
Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity, Front. Mol. Neurosci, vol.11, p.36, 2018. ,
Long-term RNAi knockdown of alpha-synuclein in the adult rat substantia nigra without neurodegeneration, Neurobiol. Dis, vol.125, pp.146-153, 2019. ,
Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra, PLoS ONE, vol.5, p.12122, 2010. ,
RNA interference targeting alpha-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells, Brain Res, pp.59-67, 1521. ,
Normalization of Overexpressed alpha-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference, Mol. Therapy Nucleic. Acids, vol.4, p.241, 2015. ,
A. shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model, J. Clin. Invest, vol.125, pp.2721-2735, 2015. ,
Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease, PLoS ONE, 2011. ,
Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice, Mov. Disord, vol.29, pp.1476-1485, 2014. ,
Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy, Nano Res, vol.10, pp.3496-3508, 2017. ,
Noninvasive delivery of an alpha-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound, Mov. Disord, vol.33, pp.1567-1579, 2018. ,
Selective alpha-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease, Mol. Therapy, vol.26, pp.550-567, 2018. ,
Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders, Mol. Therapy, vol.24, pp.746-758, 2016. ,
Systemic peptide mediated delivery of an siRNA targeting alpha-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease, Neurobiol. Dis, vol.127, pp.163-177, 2019. ,
Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of alpha-Synuclein in Primary Neuronal Cultures and in Vivo, J. Biol. Chem, vol.291, pp.8756-8772, 2016. ,
The E3 Ubiquitin Ligases TRIM17 and TRIM41 Modulate alpha-Synuclein Expression by Regulating ZSCAN21, Cell Rep, vol.25, pp.2484-2496, 2018. ,
Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease, vol.357, pp.891-898, 2017. ,
Iwatsubo, T. alpha-Synuclein is phosphorylated in synucleinopathy lesions, Nat. Cell Biol, vol.4, pp.160-164, 2002. ,
Phosphorylation of Ser-129 is the dominant pathological modification of alphasynuclein in familial and sporadic Lewy body disease, J. Biol. Chem, vol.281, pp.29739-29752, 2006. ,
Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein, J. Biol. Chem, vol.275, pp.390-397, 2000. ,
Synucleins are a novel class of substrates for G protein-coupled receptor kinases, J. Biol. Chem, vol.275, pp.26515-26522, 2000. ,
Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation, FASEB J, vol.16, pp.210-212, 2002. ,
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells, J. Neurosci, vol.25, pp.5544-5552, 2005. ,
Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease, Hum. Mol. Genet, vol.18, pp.872-887, 2009. ,
Phosphorylation of synucleins by members of the Polo-like kinase family, J. Biol. Chem, vol.285, pp.2807-2822, 2010. ,
Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease, Nat. Neurosci, vol.8, pp.657-663, 2005. ,
Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation, J. Clin. Invest, vol.119, pp.3257-3265, 2009. ,
The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease, J. Neurosci, vol.26, pp.9227-9238, 2006. ,
Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system, J. Biol. Chem, vol.284, pp.2598-2602, 2009. ,
Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau, J. Neurosci, vol.31, pp.7604-7618, 2011. ,
Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo, Proc. Natl. Acad. Sci, vol.110, pp.3945-3954, 2013. ,
Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce alphasynuclein phosphorylation in rat brain, ChemMedChem, vol.8, pp.1295-1313, 2013. ,
Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein, Int. J. Pharm, vol.514, pp.142-149, 2016. ,
Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model, J. Neurosci, vol.31, pp.6963-6971, 2011. ,
Specificity and regulation of casein kinase-mediated phosphorylation of alphasynuclein, J. Neuropathol. Exp. Neurol, vol.67, pp.402-416, 2008. ,
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo, J. Biol. Chem, vol.285, pp.17648-17661, 2010. ,
Metformin lowers Ser-129 phosphorylated alpha-synuclein levels via mTOR-dependent protein phosphatase 2A activation, Cell Death Dis, 1209. ,
Metformin lowers alpha-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease, Neuropharmacology, vol.125, pp.396-407, 2017. ,
Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits, EMBO J, vol.19, pp.5682-5691, 2000. ,
Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo, EMBO J, vol.19, pp.5672-5681, 2000. ,
Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB, Proc. Natl. Acad. Sci, vol.115, pp.12053-12062, 2018. ,
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, Am. J. Pathol, vol.152, pp.879-884, 1998. ,
Synthetic filaments assembled from C-terminally truncated alpha-synuclein, FEBS Lett, vol.436, pp.1146-1152, 1998. ,
The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease, J. Neurochem, vol.76, pp.87-96, 2001. ,
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations, Proc. Natl. Acad. Sci, vol.102, pp.2162-2167, 2005. ,
Role of alpha-synuclein carboxy-terminus on fibril formation in vitro, Biochemistry, vol.42, pp.8530-8540, 2003. ,
Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro, Biochemistry, vol.43, pp.16233-16242, 2004. ,
A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: Implications for pathogenesis of Parkinson disease, J. Biol. Chem, vol.280, pp.22670-22678, 2005. ,
Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology, Eur. J. Neurosci, vol.32, pp.409-422, 2010. ,
Distinct cleavage patterns of normal and pathologic forms of alphasynuclein by calpain I in vitro, J. Neurochem, vol.86, pp.836-847, 2003. ,
Cleavage of alpha-synuclein by calpain: Potential role in degradation of fibrillized and nitrated species of alpha-synuclein, Biochemistry, vol.44, pp.7818-7829, 2005. ,
Calpain-cleavage of alpha-synuclein: Connecting proteolytic processing to diseaselinked aggregation, Am. J. Pathol, vol.170, pp.1725-1738, 2007. ,
, , 2018.
Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]alphaSyn transgenic mice, Hum. Mol. Genet, vol.23, pp.3975-3989, 2014. ,
Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models, J. Neurosci, vol.34, pp.9441-9454, 2014. ,
Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein alpha-synuclein, Proc. Natl. Acad. Sci, vol.113, pp.9587-9592, 2016. ,
Alpha-synuclein degradation by serine protease neurosin: Implication for pathogenesis of synucleinopathies, Hum. Mol. Genet, vol.12, pp.2625-2635, 2003. ,
Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro, Neurosci. Lett, vol.436, pp.52-56, 2008. ,
Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species, Biochemistry, vol.47, pp.9678-9687, 2008. ,
Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases, J. Biol. Chem, vol.280, pp.25216-25224, 2005. ,
Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death, J. Biol. Chem, vol.286, pp.14168-14177, 2011. ,
Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins, Nature, vol.446, pp.1017-1022, 2007. ,
Cytosolic O-glycosylation is abundant in nerve terminals, J. Neurochem, vol.79, pp.1080-1089, 2001. ,
Enrichment and site mapping of O-linked N-acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry, Mol. Cell Proteom, vol.9, pp.153-160, 2010. ,
,
Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets, Proc. Natl. Acad. Sci, vol.109, pp.7280-7285, 2012. ,
O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson's disease, Nat. Chem, vol.7, pp.913-920, 2015. ,
O-GlcNAcylation of alpha-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding, ACS Chem. Biol, vol.12, pp.1020-1027, 2017. ,
O-GlcNAc modification inhibits the calpain-mediated cleavage of alpha-synuclein, Bioorg. Med. Chem, vol.25, pp.4977-4982, 2017. ,
alpha-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease, Proc. Natl. Acad. Sci, vol.116, pp.1511-1519, 2019. ,
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies, J. Med. Chem, vol.62, pp.10062-10097, 2019. ,
alpha-Synuclein immunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining, Acta Neuropathol, vol.99, pp.352-357, 2000. ,
Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions, J. Biol. Chem, vol.277, pp.49071-49076, 2002. ,
Ubiquitination of alphasynuclein is not required for formation of pathological inclusions in alpha-synucleinopathies, Am. J. Pathol, vol.163, issue.10, pp.63633-63637, 2003. ,
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function, J. Biol. Chem, vol.278, pp.44405-44411, 2003. ,
Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies, Hum. Mol. Genet, vol.28, pp.548-560, 2019. ,
The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways, J. Biol. Chem, vol.280, pp.23727-23734, 2005. ,
CHIP targets toxic alpha-Synuclein oligomers for degradation, J. Biol. Chem, vol.283, pp.17962-17968, 2008. ,
Ubiquitination of alpha-synuclein by Siah-1 promotes alphasynuclein aggregation and apoptotic cell death, Hum. Mol. Genet, vol.17, pp.906-917, 2008. ,
Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway, Proc. Natl. Acad. Sci, vol.108, pp.17004-17009, 2011. ,
Enhanced ubiquitin-dependent degradation by Nedd4 protects against alpha-synuclein accumulation and toxicity in animal models of Parkinson's disease, Neurobiol. Dis, vol.64, pp.79-87, 2014. ,
Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated alphasynuclein, Angew Chem. Int. Ed. Engl, vol.50, pp.405-409, 2011. ,
site-specific ubiquitin modification of alpha-synuclein reveals differential effects on aggregation, J. Am. Chem. Soc, vol.134, pp.5468-5471, 2012. ,
Synthetic polyubiquitinated alpha-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology, Proc. Natl. Acad. Sci, vol.110, pp.17726-17731, 2013. ,
SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation, Proc. Natl. Acad. Sci, vol.114, pp.13176-13181, 2017. ,
Sumoylation inhibits alpha-synuclein aggregation and toxicity, J. Cell Biol, vol.194, pp.49-60, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-02193319
Extent of inhibition of alpha-synuclein aggregation in vitro by SUMOylation is conjugation site-and SUMO isoform-selective, Biochemistry, vol.54, pp.959-961, 2015. ,
N-Terminal Acetylation Affects alpha-Synuclein Fibril Polymorphism, Biochemistry, vol.58, pp.3630-3633, 2019. ,
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease, Science, vol.317, pp.516-519, 2007. ,
The mechanism of sirtuin 2-mediated exacerbation of alphasynuclein toxicity in models of Parkinson disease, PLoS Biol, vol.15, p.2000374, 2017. ,
Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal-and glyoxal-glycated cysteine, arginine, and lysine residues, J. Biol. Chem, vol.290, pp.1885-1897, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01131011
Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies, vol.140, pp.1399-1419, 2017. ,
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions, Science, vol.290, pp.985-989, 2000. ,
Allostery in a disordered protein: Oxidative modifications to alpha-synuclein act distally to regulate membrane binding, J. Am. Chem. Soc, vol.133, pp.7152-7158, 2011. ,
Elucidating the Role of Site-Specific Nitration of alpha-Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis, J. Am. Chem. Soc, vol.137, pp.5041-5052, 2015. ,
Functional consequences of alpha-synuclein tyrosine nitration: Diminished binding to lipid vesicles and increased fibril formation, J. Biol. Chem, vol.279, pp.47746-47753, 2004. ,
Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease, Anal. Chem, vol.81, pp.7823-7828, 2009. ,
Passive immunization reduces behavioral and neuropathological deficits in an alphasynuclein transgenic model of Lewy body disease, PLoS ONE, 2011. ,
First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers, Mov. Disord, vol.32, pp.211-218, 2017. ,
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial, JAMA Neurol, vol.75, pp.1206-1214, 2018. ,
Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission, J. Neurosci, vol.32, pp.13454-13469, 2012. ,
Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy, Acta Neuropathol. Commun, vol.5, 2017. ,
Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo, Neurobiol. Dis, vol.132, p.104582, 2019. ,
Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration, Cell Rep, vol.7, pp.2054-2065, 2014. ,
Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson's disease, PLoS ONE, vol.10, p.116841, 2015. ,
Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models, Neurobiol. Dis, vol.124, pp.276-288, 2019. ,
Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054, Mov. Disord, vol.34, pp.1154-1163, 2019. ,
Antibodies against alpha-synuclein reduce oligomerization in living cells, PLoS ONE, 2011. ,
Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation, J. Neurochem, vol.126, pp.131-144, 2013. ,
Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice, Neurobiol. Dis, vol.69, pp.134-143, 2014. ,
Differential effects of immunotherapy with antibodies targeting alpha-synuclein oligomers and fibrils in a transgenic model of synucleinopathy, Neurobiol. Dis, vol.104, pp.85-96, 2017. ,
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease, Neuron, vol.46, pp.857-868, 2005. ,
Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human alpha-synuclein: Feasibility study, Neurosci. Lett, vol.560, pp.86-91, 2014. ,
Next-generation active immunization approach for synucleinopathies: Implications for Parkinson's disease clinical trials, Acta Neuropathol, vol.127, pp.861-879, 2014. ,
Immunotherapy for neurodegenerative diseases: Focus on alpha-synucleinopathies, Pharm. Ther, vol.138, pp.311-322, 2013. ,
Active immunization therapies for Parkinson's disease and multiple system atrophy, Mov. Disord, vol.31, pp.214-224, 2016. ,
New therapeutic approaches to target alphasynuclein in Parkinson's disease: The role of immunotherapy, Int. Rev. Neurobiol, vol.146, pp.281-295, 2019. ,
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies, J. Neurosci, vol.38, pp.1000-1014, 2018. ,
Evaluation of an alpha synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease, Hum. Vaccin Immunother, vol.11, pp.922-930, 2015. ,
Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit alpha-Synuclein Aggregation and Facilitate its Degradation, Mol. Therapy Nucleic Acids, vol.11, pp.228-242, 2018. ,
Exosomal DNA Aptamer Targeting alpha-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model, Mol. Therapy Nucleic Acids, vol.17, pp.726-740, 2019. ,
Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies, Exp. Neurobiol, vol.28, pp.547-553, 2019. ,
Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy, Cell Rep, vol.13, pp.771-782, 2015. ,
Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation, Mol. Neurodegener, vol.13, p.43, 2018. ,
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders, Neurobiol. Dis, vol.2020, p.104619 ,
Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells, Neurosci. Lett, vol.459, pp.16-18, 2009. ,
Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein, Sci. Rep, vol.8, p.17611, 2018. ,
An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity, J. Mol. Biol, vol.377, pp.136-147, 2008. ,
Exploring the role of post-translational modifications in regulating alpha-synuclein interactions by studying the effects of phosphorylation on nanobody binding, Protein Sci, vol.27, pp.1262-1274, 2018. ,
Bifunctional Anti-Non-Amyloid Component alpha-Synuclein Nanobodies Are Protective In Situ, PLoS ONE, vol.11, p.165964, 2016. ,
Proteasometargeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson's disease model, NPJ Parkinsons Dis, 2018. ,
Alpha-Synuclein as a Biomarker for Parkinson's Disease, Brain Pathol, vol.26, pp.410-418, 2016. ,
Safety and pharmacological characterization of the molecular tweezer CLR01-A broad-spectrum inhibitor of amyloid proteins' toxicity, BMC Pharm. Toxicol, vol.15, p.23, 2014. ,
Molecular Lysine Tweezers Counteract Aberrant Protein Aggregation, Front. Chem, vol.7, p.657, 2019. ,
A novel "molecular tweezer" inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo, Neurotherapeutics, vol.9, pp.464-476, 2012. ,
Molecular basis for preventing alpha-synuclein aggregation by a molecular tweezer, J. Biol. Chem, vol.289, pp.10727-10737, 2014. ,
A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing alpha-Synuclein, Neurotherapeutics, vol.14, pp.1107-1119, 2017. ,
Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration, FEBS J, vol.272, pp.3661-3672, 2005. ,
Modulation of alpha-synuclein aggregation by dopamine analogs, PLoS ONE, vol.5, p.9234, 2010. ,
Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model, Sci. Rep, vol.6, 2016. ,
An ortho-Iminoquinone Compound Reacts with Lysine Inhibiting Aggregation while Remodeling Mature Amyloid Fibrils, ACS Chem. Neurosci, vol.8, pp.1704-1712, 2017. ,
Membraneinduced folding of the cAMP-regulated phosphoprotein endosulfine-alpha, Biochemistry, vol.47, pp.12357-12364, 2008. ,
Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy, J. Biol. Chem, vol.282, pp.34555-34567, 2007. ,
Endosulfine-alpha inhibits membrane-induced alpha-synuclein aggregation and protects against alphasynuclein neurotoxicity, Acta Neuropathol. Commun, vol.5, 2017. ,
Fasudil attenuates aggregation of ?-synuclein in models of Parkinson's disease, Acta Neuropathol. Commun, vol.4, 2016. ,
Ade novocompound targeting ?-synuclein improves deficits in models of Parkinson's disease, Brain, vol.139, pp.3217-3236, 2016. ,
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease, Sci. Rep, vol.8, 2018. ,
Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease, Acta Neuropathol, vol.125, pp.795-813, 2013. ,
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset, Acta Neuropathol, vol.127, pp.779-780, 2014. ,
Depopulation of dense ?-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model, Acta Neuropathol, vol.138, pp.575-595, 2019. ,
Chaperone machines for protein folding, unfolding and disaggregation, Nat. Rev. Mol. Cell Biol, vol.14, pp.630-642, 2013. ,
Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies, Am. J. Pathol, vol.168, pp.947-961, 2006. ,
Heatshock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity, FASEB J, vol.25, pp.326-336, 2011. ,
Heat shock prevents alpha-synucleininduced apoptosis in a yeast model of Parkinson's disease, J. Mol. Biol, vol.351, pp.1081-1100, 2005. ,
Pharmacological prevention of Parkinson disease in Drosophila, Nat. Med, vol.8, pp.1185-1186, 2002. ,
Chaperone suppression of alphasynuclein toxicity in a Drosophila model for Parkinson's disease, Science, vol.295, pp.865-868, 2002. ,
Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila, J. Biol. Chem, vol.280, pp.2873-2878, 2005. ,
Geldanamycin Induces Heat Shock Protein 70 and Protects against MPTP-induced Dopaminergic Neurotoxicity in Mice, J. Biol. Chem, vol.280, pp.39962-39969, 2005. ,
Rab11a and HSP90 Regulate Recycling of Extracellular [alpha]-Synuclein, J. Neurosci, vol.29, pp.1480-1485, 2009. ,
Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent ?-Synuclein Oligomer Formation and Rescue ?-Synuclein-Induced Toxicity, J. Pharmacol. Exp. Ther, vol.332, pp.849-857, 2010. ,
17-AAG Induces Cytoplasmic ?-Synuclein Aggregate Clearance by Induction of Autophagy, PLoS ONE, vol.5, p.8753, 2010. ,
The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein, J. Biol. Chem, vol.284, pp.31190-31199, 2009. ,
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity, J. Biol. Chem, vol.279, pp.25497-25502, 2004. ,
Impairment of redox state and dopamine level induced by alpha-synuclein aggregation and the prevention effect of hsp70, Biochem. Biophys. Res. Commun, vol.331, pp.278-284, 2005. ,
Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies, Perspect Med. Chem, vol.2, pp.41-49, 2008. ,
Geldanamycin induces Hsp70 and prevents alphasynuclein aggregation and toxicity in vitro, Biochem. Biophys. Res. Commun, vol.321, pp.665-669, 2004. ,
Chemical induction of Hsp70 reduces alpha-synuclein aggregation in neuroglioma cells, ACS Chem. Biol, vol.8, pp.1460-1468, 2013. ,
Ubiquitinylation of alphasynuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5), PLoS ONE, 2011. ,
Hsp70 gene transfer by adeno-associated virus inhibits MPTPinduced nigrostriatal degeneration in the mouse model of Parkinson disease, Mol. Therapy, vol.11, pp.80-88, 2005. ,
Heat shock protein 70 inhibits alphasynuclein fibril formation via preferential binding to prefibrillar species, J. Biol. Chem, vol.280, pp.14733-14740, 2005. ,
Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates, J. Mol. Biol, vol.364, pp.323-336, 2006. ,
Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly, Biochemistry, vol.47, pp.12614-12625, 2008. ,
Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease, J. Clin. Invest, vol.118, pp.3087-3097, 2008. ,
Hsp110 mitigates ?-synuclein pathology in vivo, Proc. Natl. Acad. Sci, vol.116, pp.24310-24316, 2019. ,
Molecular pathology of Lewy body diseases, Int. J. Mol. Sci, vol.10, pp.724-745, 2009. ,
?-Synuclein Is Degraded by Both Autophagy and the Proteasome, J. Biol. Chem, vol.278, pp.25009-25013, 2003. ,
Impaired Degradation of Mutant ?-Synuclein by Chaperone-Mediated Autophagy, Science, vol.305, p.1292, 2004. ,
Clearance of ?-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway, J. Neurosci, vol.24, p.1888, 2004. ,
Altered Proteasomal Function in Sporadic Parkinson's Disease, Exp. Neurol, vol.179, pp.38-46, 2003. ,
Alpha-synuclein and protein degradation pathways in Parkinson's disease: A pathological feed-back loop, Exp. Neurol, vol.247, pp.308-313, 2013. ,
Proteasomal inhibition leads to formation of ubiquitin/?synuclein-immunoreactive inclusions in PC12 cells, J. Neurochem, vol.78, pp.899-908, 2001. ,
Cell-produced ?-synuclein oligomers are targeted to, and impair, the 26S proteasome, Neurobiol. Aging, vol.31, pp.953-968, 2010. ,
Aggregated and Monomeric ?-Synuclein Bind to the S6? Proteasomal Protein and Inhibit Proteasomal Function, J. Biol. Chem, vol.278, pp.11753-11759, 2003. ,
The role of ubiquitin linkages on ?-synuclein induced-toxicity in aDrosophilamodel of Parkinson's disease, J. Neurochem, vol.110, pp.208-219, 2009. ,
Protective effects of salidroside in the MPTP/MPP(+)-induced model of Parkinson's disease through ROS-NO-related mitochondrion pathway, Mol. Neurobiol, vol.51, pp.718-728, 2015. ,
Salidroside Promotes the Pathological alpha-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells, Front. Pharm, vol.9, p.377, 2018. ,
, Proteasome Activation by Small Molecules. Cell Chem. Biol, vol.24, pp.725-736, 2017.
,
Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models, Neurotherapeutics, 2019. ,
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of ?-synuclein, J. Neurosci. Off. J. Soc. Neurosci, vol.31, pp.14508-14520, 2011. ,
Lysosomal degradation of alpha-synuclein in vivo, J. Biol. Chem, vol.285, pp.13621-13629, 2010. ,
Wild type alpha-synuclein is degraded by chaperonemediated autophagy and macroautophagy in neuronal cells, J. Biol. Chem, vol.283, pp.23542-23556, 2008. ,
Chaperone-mediated autophagy markers in Parkinson disease brains, Arch. Neurol, vol.67, pp.1464-1472, 2010. ,
Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease, Mov. Disord, vol.30, pp.1639-1647, 2015. ,
Dopamine-modified alpha-synuclein blocks chaperonemediated autophagy, J. Clin. Invest, vol.118, pp.777-788, 2008. ,
Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy, PLoS ONE, vol.4, p.5515, 2009. ,
Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy, Science, vol.323, pp.124-127, 2009. ,
Boosting chaperone-mediated autophagy in vivo mitigates alpha-synuclein-induced neurodegeneration, Brain, vol.136, pp.2130-2146, 2013. ,
Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives, Nat. Chem. Biol, vol.9, pp.374-382, 2013. ,
Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease, Cell Death Dis, 2013. ,
Geniposide reduces alpha-synuclein by blocking microRNA-21/lysosomeassociated membrane protein 2A interaction in Parkinson disease models, Brain Res, vol.1644, pp.98-106, 2016. ,
Could miRNA expression changes be a reliable clinical biomarker for Parkinson's disease?, Neurodegener. Dis. Manag, vol.3, pp.455-465, 2013. ,
Pathogenic lysosomal depletion in Parkinson's disease, J. Neurosci, vol.30, pp.12535-12544, 2010. ,
Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions, Neurobiol. Dis, vol.35, pp.385-398, 2009. ,
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration, Proc. Natl. Acad. Sci, vol.109, pp.9611-9616, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01290058
ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies, Acta Neuropathol. Commun, vol.1, pp.11-11, 2013. ,
,
, Parkinson's disease and dementia with Lewy bodies, Mol. Neurodegener, vol.10, p.15, 2015.
Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies, Mol. Neurobiol, vol.56, pp.1344-1355, 2019. ,
Path mediation analysis reveals GBA impacts Lewy body disease status by increasing ?-synuclein levels, Neurobiol. Dis, vol.121, pp.205-213, 2019. ,
Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice, Sci. Rep, 2018. ,
alpha-Synuclein impairs macroautophagy: Implications for Parkinson's disease, J. Cell Biol, vol.190, pp.1023-1037, 2010. ,
HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: A process modulated by the natural autophagy inducer corynoxine B, Autophagy, vol.10, pp.144-154, 2014. ,
Synuclein oligomers distinctively permeabilize complex model membranes, FEBS J, vol.281, pp.2838-2850, 2014. ,
Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy, PLoS ONE, vol.5, p.9313, 2010. ,
Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy, Pathobiol. Aging Age Relat. Dis, vol.5, p.28743, 2015. ,
TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity, Proc. Natl. Acad. Sci, vol.110, pp.1817-1826, 2013. ,
Fighting neurodegeneration with rapamycin: Mechanistic insights, Nat. Rev. Neurosci, vol.12, pp.437-452, 2011. ,
Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of alpha-synuclein via SIRT1-deacetylated LC3, Mol. Nutr Food Res, vol.60, pp.2161-2175, 2016. ,
MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting alpha-synuclein expression in MPTP-induced Parkinson's disease mouse, Biomed. Pharm, vol.74, pp.252-256, 2015. ,
Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease, Neuroscience, vol.284, pp.900-911, 2015. ,
, Gene Network Regulating Lysosomal Biogenesis and Function. Science, vol.325, pp.473-477, 2009.
TFEB regulates autophagy: An integrated coordination of cellular degradation and recycling processes, Autophagy, vol.7, pp.1379-1381, 2011. ,
, TFEB links autophagy to lysosomal biogenesis, vol.332, pp.1429-1433, 2011.
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB, EMBO J, vol.31, pp.1095-1108, 2012. ,
The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective, Trends Neurosci, vol.39, pp.221-234, 2016. ,
Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies, JCI Insight, vol.4, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02346929
Overexpression of TFEB Drives a Pleiotropic Neurotrophic Effect and Prevents Parkinson's Disease-Related Neurodegeneration, Mol. Therapy, vol.26, pp.1552-1567, 2018. ,
Genetic and chemical activation of TFEB mediates clearance of aggregated alpha-synuclein, PLoS ONE, vol.10, p.120819, 2015. ,
2-Hydroxypropyl-beta-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: Implications for therapy, J. Biol. Chem, vol.289, pp.10211-10222, 2014. ,
Pomegranate activates TFEB to promote autophagy-lysosomal fitness and mitophagy, Sci. Rep, vol.9, p.727, 2019. ,
Effect of trehalose on PC12 cells overexpressing wild-type or A53T mutant alpha-synuclein, Neurochem. Res, vol.37, pp.2025-2032, 2012. ,
Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein, J. Biol. Chem, vol.282, pp.5641-5652, 2007. ,
Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose, Sci. Rep, vol.9, p.544, 2019. ,
Trehalose intake induces chaperone molecules along with autophagy in a mouse model of Lewy body disease, Biochem. Biophys. Res. Commun, vol.465, pp.746-752, 2015. ,
Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis, Sci. Signal, vol.9, pp.21-21, 2016. ,
Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease, J. Pharm. Exp. Ther, vol.369, pp.364-374, 2019. ,
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models, Hum. Mol. Genet, vol.22, pp.3315-3328, 2013. ,
c-Abl phosphorylates alpha-synuclein and regulates its degradation: Implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's disease, Hum. Mol. Genet, vol.23, pp.2858-2879, 2014. ,
Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies, J. Parkinson's Dis, vol.6, pp.503-517, 2016. ,
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease, Pharmacol. Res. Perspect, vol.7, p.470, 2019. ,
Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases, J. Neurosci, vol.29, pp.13578-13588, 2009. ,
Beclin1 and HMGB1 ameliorate the alphasynuclein-mediated autophagy inhibition in PC12 cells, Diagn. Pathol, vol.11, p.15, 2016. ,
Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy, Autophagy, vol.8, pp.98-108, 2012. ,
Coffee and Health: A Review of Recent Human Research, Crit. Rev. Food Sci. Nutr, vol.46, pp.101-123, 2006. ,
Chronic Caffeine Treatment Protects Against alpha-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum, Front. Neurosci, vol.12, p.301, 2018. ,
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells, Neurobiol. Dis, vol.82, pp.235-242, 2015. ,
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells, Brain, vol.137, pp.1481-1495, 2014. ,
CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy, Proc. Natl. Acad. Sci, vol.108, pp.12101-12106, 2011. ,
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains, Ann. Neurol, vol.72, pp.455-463, 2012. ,
Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease, Brain, vol.137, pp.834-848, 2014. ,
Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies, Cell, vol.146, pp.37-52, 2011. ,
Reversible Conformational Conversion of alpha-Synuclein into Toxic Assemblies by Glucosylceramide, Neuron, vol.97, pp.92-107, 2018. ,
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological alpha-Synuclein Insult, Neuron, 2019. ,
Krainc, D. alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models, Proc. Natl. Acad. Sci, vol.113, pp.1931-1936, 2016. ,
Glucocerebrosidase and its relevance to Parkinson disease, Mol. Neurodegener, vol.14, p.36, 2019. ,
Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice, Ann. Neurol, vol.80, pp.766-775, 2016. ,
Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study, Ann. Clin. Transl. Neurol, vol.3, pp.200-215, 2016. ,
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial, BMC Neurol, 1920. ,
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial, JAMA Neurol, vol.2020 ,
The iminosugar isofagomine increases the activity of N370S mutant acid ?-glucosidase in Gaucher fibroblasts by several mechanisms, Proc. Natl. Acad. Sci, vol.103, p.13813, 2006. ,
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase, FEBS J, vol.277, pp.1618-1638, 2010. ,
Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease, J. Biol. Chem, vol.287, pp.4275-4287, 2012. ,
Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones, Proc. Natl. Acad. Sci, vol.110, pp.966-971, 2013. ,
A GCase chaperone improves motor function in a mouse model of synucleinopathy, Neurotherapeutics, vol.11, pp.840-856, 2014. ,
A New Glucocerebrosidase Chaperone Reduces alpha-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism, J. Neurosci, vol.36, pp.7441-7452, 2016. ,
Activation of beta-Glucocerebrosidase Reduces Pathological alpha-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons, J. Neurosci, vol.36, pp.7693-7706, 2016. ,
A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease, Sci. Transl. Med, p.11, 2019. ,
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity, Mol. Brain, vol.1, p.17, 2008. ,
Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease, Pharm. Biochem. Behav, vol.177, pp.1-11, 2019. ,
Curcumin modulates alpha-synuclein aggregation and toxicity, ACS Chem. Neurosci, vol.4, pp.393-407, 2013. ,
Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro, J. Neurochem, vol.97, pp.105-115, 2006. ,
Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS, Biochim. Biophys. Acta (BBA) Proteins Proteom, vol.1784, pp.1570-1577, 2008. ,
Curcumin binds to the pre-fibrillar aggregates of Cu/Zn superoxide dismutase (SOD1) and alters its amyloidogenic pathway resulting in reduced cytotoxicity, Biochim. Biophys. Acta, vol.1854, pp.426-436, 2015. ,
Curcumin Prevents Aggregation in ?-Synuclein by Increasing Reconfiguration Rate, J. Biol. Chem, vol.287, pp.9193-9199, 2012. ,
Polyphenols in combination with ?-cyclodextrin can inhibit and disaggregate ?-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative, Biochim. Biophys. Acta (BBA) Proteins Proteom, vol.1865, pp.589-603, 2017. ,
The use of nanopore analysis for discovering drugs which bind to ?-synuclein for treatment of Parkinson's disease, Eur. J. Med. Chem, vol.88, pp.42-54, 2014. ,
Curcumin reduces ?-synuclein induced cytotoxicity in Parkinson's disease cell model, BMC Neurosci, vol.11, 2010. ,
Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism, Pharmacol. Res, vol.63, pp.439-444, 2011. ,
Curcumin Treatment Improves Motor Behavior in alpha-Synuclein Transgenic Mice, PLoS ONE, vol.10, p.128510, 2015. ,
Curcumin affords neuroprotection and inhibits ?-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model, Inflammopharmacology, vol.26, pp.349-360, 2017. ,
Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant ?-Synuclein, Sci. Rep, vol.5, 2015. ,
Small molecules interacting with ?-synuclein: Antiaggregating and cytoprotective properties, Amino Acids, vol.45, pp.327-338, 2013. ,
Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits alpha-synuclein oligomer formation: Relevance to Parkinson's disease, Curr. Pharm Des, vol.18, pp.76-84, 2012. ,
Curcumin-Loaded Amine-Functionalized Mesoporous Silica Nanoparticles Inhibit ?-Synuclein Fibrillation and Reduce Its Cytotoxicity-Associated Effects, Langmuir, vol.32, pp.13394-13402, 2016. ,
Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson's Disease, ACS Chem. Neurosci, vol.7, pp.1658-1670, 2016. ,
Neuroprotective effect of curcumin-loaded lactoferrin nano particles against rotenone induced neurotoxicity, Neurochem. Int, vol.95, pp.37-45, 2016. ,
beta-cyclodextrin and curcumin, a potent cocktail for disaggregating and/or inhibiting amyloids: A case study with alpha-synuclein, Biochemistry, vol.53, pp.4081-4083, 2014. ,
Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy, Theranostics, vol.8, pp.2264-2277, 2018. ,
Gallic Acid and Gallates in Human Health and Disease: Do Mitochondria Hold the Key to Success?, Mol. Nutr. Food Res, vol.62, p.1700699, 2018. ,
Structure activity relationship of phenolic acid inhibitors of ?-synuclein fibril formation and toxicity. Front, Aging Neurosci, vol.6, 2014. ,
Gallic acid interacts with ?-synuclein to prevent the structural collapse necessary for its aggregation, Biochim. Biophys. Acta (BBA) Proteins Proteom, vol.1844, pp.1481-1485, 2014. ,
Tyrosol, a simple phenol from EVOO, targets multiple pathogenic mechanisms of neurodegeneration in a C. elegans model of Parkinson's disease, Neurobiol. Aging, vol.82, pp.60-68, 2019. ,
Flavones from root of Scutellaria baicalensis Georgi: Drugs of the future in neurodegeneration?, CNS Neurol. Disord. Drug Targets, vol.10, pp.184-191, 2011. ,
Molecular mechanisms underlying the flavonoidinduced inhibition of alpha-synuclein fibrillation, Biochemistry, vol.48, pp.8206-8224, 2009. ,
Inhibition and disaggregation of ?synuclein oligomers by natural polyphenolic compounds, FEBS Lett, vol.585, pp.1113-1120, 2011. ,
Polyphenolic compounds are novel protective agents against lipid membrane damage by ?-synuclein aggregates in vitro, Biochim. Biophys. Acta (BBA) Biomembr, vol.1818, pp.2502-2510, 2012. ,
Neuroprotective effects of baicalein in animal models of Parkinson's disease: A systematic review of experimental studies, Phytomedicine, vol.55, pp.302-309, 2019. ,
Baicalein inhibits formation of alpha-synuclein oligomers within living cells and prevents Abeta peptide fibrillation and oligomerisation, Chembiochem, vol.12, pp.615-624, 2011. ,
Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein, J. Mol. Biol, vol.383, pp.214-223, 2008. ,
Baicalein blocks alpha-synuclein secretion from SN4741 cells and facilitates alpha-synuclein polymerization to big complex, Neurosci. Lett, vol.655, pp.109-114, 2017. ,
Single Particle Characterization of Iron-induced Pore-forming ?-Synuclein Oligomers, J. Biol. Chem, vol.283, pp.10992-11003, 2008. ,
Baicalein inhibits alpha-synuclein oligomer formation and prevents progression of alpha-synuclein accumulation in a rotenone mouse model of Parkinson's disease, Biochim. Biophys. Acta, vol.1862, pp.1883-1890, 2016. ,
Baicalein attenuates alpha-synuclein aggregation, inflammasome activation and autophagy in the MPP(+)-treated nigrostriatal dopaminergic system in vivo, J. Ethnopharmacol, vol.194, pp.522-529, 2016. ,
Cuminaldehyde as the Major Component of Cuminum cyminum, a Natural Aldehyde with Inhibitory Effect on Alpha-Synuclein Fibrillation and Cytotoxicity, J. Food Sci, vol.80, pp.2336-2345, 2015. ,
Essential Oils May Lead alpha-Synuclein towards Toxic Fibrils Formation, Parkinsons Dis, p.6219249, 2016. ,
Looking for a generic inhibitor of amyloid-like fibril formation among flavone derivatives, PeerJ, vol.3, p.1271, 2015. ,
Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro, Brain Res, pp.17-26, 1651. ,
Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease, Neurochem. Res, vol.41, pp.2788-2796, 2016. ,
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers, Nat. Struct Mol. Biol, vol.15, pp.558-566, 2008. ,
EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity, Proc. Natl. Acad. Sci, vol.107, pp.7710-7715, 2010. ,
Anti-pruritic effect of baicalin and its metabolites, baicalein and oroxylin A, in mice, Acta Pharm. Sin, vol.31, pp.718-724, 2010. ,
Influence of EGCG on alpha-synuclein (alphaS) aggregation and identification of their possible binding mode: A computational study using molecular dynamics simulation, Chem. Biol. Drug Des, vol.91, pp.162-171, 2018. ,
How epigallocatechin gallate can inhibit alpha-synuclein oligomer toxicity in vitro, J. Biol. Chem, vol.289, pp.21299-21310, 2014. ,
EGCG-mediated Protection of the Membrane Disruption and Cytotoxicity Caused by the 'Active Oligomer' of alpha-Synuclein, Sci. Rep, vol.7, p.17945, 2017. ,
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic, Biol. Med, vol.62, pp.52-64, 2013. ,
Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils, J. Am. Chem. Soc, vol.135, pp.7503-7510, 2013. ,
Cell-addictive" dualtarget traceable nanodrug for Parkinson's disease treatment via flotillins pathway, Theranostics, vol.8, pp.5469-5481, 2018. ,
Black tea theaflavins inhibit formation of toxic amyloid-beta and alpha-synuclein fibrils, Biochemistry, vol.50, pp.10624-10636, 2011. ,
Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria, Free Radic. Res, vol.20, pp.375-386, 1994. ,
Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic, Biol. Med, vol.22, pp.391-400, 1997. ,
Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity, Exp. Neurol, vol.132, issue.95, pp.90033-90033, 1995. ,
Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism, J. Neurochem, vol.104, pp.1613-1621, 2008. ,
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases, J. Neurochem, vol.109, pp.1427-1439, 2009. ,
Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline, Arch. Neurol, vol.59, pp.1541-1550, 2002. ,
Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids, Antioxid. Redox. Signal, vol.11, pp.439-448, 2009. ,
Molecular signaling of ginsenosides Rb1, Rg1, and Rg3 and their mode of actions, J. Ginseng. Res, vol.42, pp.123-132, 2018. ,
Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils, Neurobiol. Dis, vol.74, pp.89-101, 2015. ,
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting alpha-synuclein abnormalities in the substantia nigra, Toxicol. Lett, vol.243, pp.7-21, 2016. ,
Panax ginseng is neuroprotective in a novel progressive model of Parkinson's disease, Exp. Gerontol, vol.50, pp.95-105, 2014. ,
Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor, Biochem. Biophys. Res. Commun, vol.251, pp.471-476, 1998. ,
Apelin-36 exerts the cytoprotective effect against MPP+-induced cytotoxicity in SH-SY5Y cells through PI3K/Akt/mTOR autophagy pathway, Life Sci, vol.224, pp.95-108, 2019. ,
Apelin-36 mediates neuroprotective effects by regulating oxidative stress, autophagy and apoptosis in MPTPinduced Parkinson's disease model mice, Brain Res, p.146493, 1726. ,
Reprint of: Nrf2/ARE-mediated antioxidant actions of proelectrophilic drugs. Free Radic, Biol. Med, vol.66, pp.45-57, 2014. ,
Nrf2 mitigates LRRK2-and ?-synuclein-induced neurodegeneration by modulating proteostasis, Proc. Natl. Acad. Sci, vol.114, pp.1165-1170, 2017. ,
Anti-Inflammatory, Anticholinesterase, and Antioxidant Potential of Scopoletin Isolated from Canarium patentinervium Miq, Burseraceae Kunth). Evid. Based. Complement. Altern. Med, vol.734824, 2013. ,
, Morinda citrifolia and Its Active Principle Scopoletin Mitigate Protein Aggregation and Neuronal Apoptosis through Augmenting the DJ
, Oxidative Med. Cell. Longev, pp.1-13, 2019.
Activation of the Nrf2 signaling pathway and neuroprotection of nigral dopaminergic neurons by a novel synthetic compound KMS99220, Neurochem. Int, vol.112, pp.96-107, 2018. ,
Calcium(II) selectively induces alphasynuclein annular oligomers via interaction with the C-terminal domain, Protein Sci, vol.13, pp.3245-3252, 2004. ,
Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease, Proc. Natl. Acad. Sci, vol.102, pp.4294-4299, 2005. ,
Interaction of alpha-synuclein with divalent metal ions reveals key differences: A link between structure, binding specificity and fibrillation enhancement, J. Am. Chem. Soc, vol.128, pp.9893-9901, 2006. ,
High Dietary Iron Supplement Induces the Nigrostriatal Dopaminergic Neurons Lesion in Transgenic Mice Expressing Mutant A53T Human Alpha-Synuclein. Front, Aging Neurosci, vol.10, p.97, 2018. ,
Iron Pathophysiology in Parkinson Diseases, Adv. Exp. Med. Biol, vol.1173, pp.45-66, 2019. ,
Iron-induced oxidative stress contributes to alpha-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2, Neurochem. Int, vol.125, pp.127-135, 2019. ,
Targeting chelatable iron as a therapeutic modality in Parkinson's disease, Antioxid. Redox. Signal, vol.21, pp.195-210, 2014. ,
Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation, Neuromol. Med, vol.19, pp.309-321, 2017. ,
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease, Sci. Rep, vol.7, p.1398, 2017. ,
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein rAAV Parkinson's model, Exp. Neurol, vol.247, pp.45-58, 2013. ,
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease, Neuron, vol.37, pp.899-909, 2003. ,
Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice, ACS Chem. Neurosci, vol.7, pp.119-129, 2016. ,
l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease, J. Neurochem, vol.150, pp.88-106, 2019. ,
The novel mitochondrial iron chelator 5-((methylamino)methyl)-8-hydroxyquinoline protects against mitochondrial-induced oxidative damage and neuronal death, Biochem. Biophys. Res. Commun, vol.463, pp.787-792, 2015. ,
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats, Neuropharmacology, vol.46, pp.254-263, 2004. ,
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases, Bioorg. Med. Chem, vol.13, pp.773-783, 2005. ,
A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease, ACS Chem. Neurosci, vol.8, pp.723-730, 2017. ,
A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses alpha-syn-and MPTP-induced toxicities in vivo, Neuropharmacology, vol.123, pp.88-99, 2017. ,
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease, Acta Neuropathol. Commun, vol.5, p.53, 2017. ,
Rosmarinic acid antagonized 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in MES23.5 dopaminergic cells, Int. J. Toxicol, vol.29, pp.625-633, 2010. ,
Rosmarinic acid protects against MPTP-induced toxicity and inhibits iron-induced alpha-synuclein aggregation, Neuropharmacology, vol.144, pp.291-300, 2019. ,
Translation of the intrinsically disordered protein alpha-synuclein is inhibited by a small molecule targeting its structured mRNA, Proc. Natl. Acad. Sci, vol.2020 ,
Copper(II) and the pathological H50Q alpha-synuclein mutant: Environment meets genetics, Commun. Integr. Biol, vol.10, p.1270484, 2017. ,
Phosphorylated alpha-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease, p.9164754, 2017. ,
ATP13A2/PARK9 regulates secretion of exosomes and alphasynuclein, J. Neurosci, vol.34, pp.15281-15287, 2014. ,
+) dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation, Hum. Mol. Genet, vol.23, issue.2, pp.2791-2801, 2014. ,
Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: Resemblance to sporadic Parkinson's disease, Mol. Cell Biochem, vol.444, pp.149-160, 2018. ,
?)-Epigallocatechin-3-gallate (EGCG) inhibits fibrillation, disaggregates amyloid fibrils of ?-synuclein, and protects PC12 cells against ?synuclein-induced toxicity, vol.7, pp.32508-32517, 2017. ,
Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of alpha-Synuclein, Molecules, vol.24, p.2040, 2019. ,
Metal chelator EGCG attenuates Fe(III)-induced conformational transition of alpha-synuclein and protects AS-PC12 cells against Fe(III)-induced death, J. Neurochem, vol.143, pp.136-146, 2017. ,
Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease, Int. Immunopharmacol, vol.4, pp.1307-1318, 2004. ,
Dexamethasone Inhibits Copper-Induced Alpha-Synuclein Aggregation by a Metallothionein-Dependent Mechanism, Neurotox Res, vol.33, pp.229-238, 2018. ,
Neuroprotection for Parkinson's disease: A call for clinically driven experimental design, Lancet. Neurol, vol.2, p.393, 2003. ,
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease, J. Neurosci, vol.21, pp.6853-6861, 2001. ,
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease, Brain, vol.136, pp.2419-2431, 2013. ,
APOE genotype regulates pathology and disease progression in synucleinopathy, Sci. Transl. Med, vol.12, 2020. ,
APOE4 exacerbates alpha-synuclein pathology and related toxicity independent of amyloid, Sci. Transl. Med, vol.12, 2020. ,